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Two novel ADAMTS13 gene mutations in thrombotic throm-
bocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
Background. Thrombotic thrombocytopenic purpura (TTP)
and hemolytic-uremic syndrome (HUS) are now considered to
be variants of one single syndrome called thrombotic throm-
bocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
Key features are thrombocytopenia, hemolytic anemia, and
subsequently impaired function of different organs, especially
the kidneys and the central nervous system (CNS). One possi-
ble reason is the deficiency of von Willebrand factor-cleaving
protease (vWF-CP) resulting in persistence of uncleaved, ul-
tralarge von Willebrand factor multimers (ULvWFM).
Methods. We report a patient who was initially diagnosed
with Evans syndrome (hemolytic anemia and autoimmune
thrombocytopenia) as infant. At 10 years of age he developed
HUS-like disease with gastrointestinal tract infection,
hemolytic anemia, thrombocytopenia,and acute renal failure.
However, enteropathogenic Escherichia coli–like or Shiga-like
toxins were not detected.
Results. Further investigations revealed severe deficiency
(<3%; normal >40%) of vWF-CP activity caused by compound
heterozygosity of two novel ADAMTS13 gene mutations (1170
G>C [W390C] and 3735 G>A [W1245X]. vWF-CP autoanti-
bodies were not detected. Periodic (every 2 weeks) treatment
with fresh frozen plasma (FFP) maintained both platelet level
and kidney function within normal range and prevented new
episodes of TTP/HUS.
Conclusion. Enteropathogenic E. coli– and Shiga-like toxin-
negative patients who present with hemolytic or thrombocy-
topenic episodes and HUS like symptoms should be tested
for vWF-CP deficiency and other noninfectious reasons for
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TTP/HUS since plasma substitution possibly provides an ef-
ficient therapeutic option for this subgroup of patients.
Today, thrombotic thrombocytopenic purpura (TTP),
first described by Moschcowitz in 1924 [1], and hemolytic-
uremic syndrome (HUS), first described by Gasser et al
in 1955 [2], are considered to be variants of one single
syndrome called thrombotic thrombocytopenic purpura/
hemolytic-uremic syndrome (TTP/HUS) [3]. Common
symptoms are formation of hyaline thrombi containing
large amounts of von Willebrand factor (vWF), asso-
ciated with thrombocytopenia, hemolytic anemia, and
subsequently impaired function of different organ sys-
tems. TTP often is complicated by neurologic symptoms,
whereas renal abnormalities prevail in HUS [3, 4].
Responsible are ultralarge vWF multimers
(ULvWFM) [5], which were first identified in a pa-
tient with TTP [6], but later also detected in patients with
HUS [7]. Persistence of ULvWFM is caused by a process-
ing defect of vWF through an acquired (autoantibodies)
or congenital (ADAMTS13 gene mutations) deficiency
of vWF-cleaving protease (vWF-CP). vWF-CP is a
vWF-specific metalloprotease [8, 9] of the ADAMTS (a
disintegrin and metalloprotease, with thrombospondin-
1–like domains) family [10–13], which physiologically
cleaves vWF at a defined position (Tyr1605 – Met1606)
after synthesis and secretion by endothelial cells [14].
If vWF-CP is deficient, ULvWFM persist and mediate
adhesion and aggregation of circulating platelets at sites
of high intravascular shear stress [15]. As a result, large,
potentially occlusive platelet thrombi appear [5].
We present the case of a boy with severe vWF-CP defi-
ciency caused by compound heterozygosity of two novel
ADAMTS13 gene mutations (1170 G>C [W390C] and
3735 G>A [W1245X] with both parents being heterozy-
gous for one mutation, each.
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METHODS
Patient
We report a boy of a German father and a Portuguese
mother. The parents are healthy and not consanguineous.
At the age of 3 years the child developed recurrent
episodes of hemolytic anemia and thrombocytopenia.
Screening for autoantibodies against vWF-CP remained
negative. Malignant disease of the hematopoetic system
was excluded by bone marrow biopsy. Therapy, before
the diagnosis of vWF-CP deficiency was made at 10 years
of age, included initially steroids and repeated transfu-
sions of platelets; splenectomy was performed at 5 years
of age; afterwards, the clinical course was uneventful for
years.
At 10 years of age he developed HUS-like disease
with diarrhea and typical laboratory findings, including
hemolytic anemia (hemoglobin 7.1 g/dL), fragmented red
cells, thrombocytopenia (<15,000/lL), elevated lactate
dehydrogenase (LDH) (5510 U/L), low fibrinogen levels
(<50 mg/dL), and acute renal failure [serum creatinine
756.7 lmol/L and blood urea nitrogen (BUN) 274 mg/
dL]. To prevent bleeding, platelets and fresh frozen
plasma (FFP) were given. Hemodialysis was performed
for 7 days. Furthermore, liver [glutamate-oxalacetate-
transaminase (GOT) 1290 U/L and glutamate-pyruvate-
transaminase (GPT) 428 U/L] and pancreatic (amylase
980 U/L and lipase 2800 U/L) enzymes were elevated.
Increased creatine kinase (5317 U/L) and troponin T
(26.4 lg/L) indicated affection of skeletal and cardiac
muscle. Echocardiographic examination showed pericar-
diac effusion and markedly impaired shortening fraction.
A broad spectrum investigation for viral [including cy-
tomegalovirus (CMV), Epstein-Barr virus (EBV), Parvo
B19 virus, BK virus, adenovirus, and Coxsackie virus]
and bacterial infection (including leptospirosis) was per-
formed with negative result. Both, enteropathogenic
Escherichia coli–like and Shiga-like toxins were negative.
RESULTS
vWF-CP deficiency
Serologic examinations revealed severe deficiency of
vWF-CP activity (<3%; normal >40%), while acitivity
of vWF itself was increased (>200%; normal 50% to
150%). vWF-CP autoantibodies were not present. How-
ever, molecular genetic analysis revealed heterozygosity
for two novel ADAMTS13 gene mutations (1170 G>C
[W390C] and 3735 G>A [W1245X]. The patient’s father
and mother showed vWF-CP levels of 28% and 27%
of normal, respectively, which is characteristic for un-
affected heterozygous carriers of ADMTS13 mutations
(Fig. 1) (R. Schneppenheim, personal communication).
Since so far no curative treatment is available for
VWF-CP deficiency, the missing plasma factor has to
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Fig. 1. Pedigree of the index patient (II).
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Fig. 2. Time course of platelet (), lactate dehydrogenase (LDH) (),
and serum creatinine () over two completed treatment cycles. With
about 10 mL fresh frozen plasma (FFP) per kilogram body weight given
only following 3 to 4 weeks, platelets dropped to <10,000/lL prior to
the next infusion. Therefore, 2-week treatment cycles were chosen for
the future.
be replaced by plasma substitution. Therefore we in-
duced periodical (every 2 weeks) infusion of about
10 mL fresh frozen plasma (FFP) per kilogram body
weight. Under this treatment, kidney function recov-
ered completely, and hemodialysis could be discontinued
(Fig. 2). Increased enzymes, pathologic changes in plasma
coagulation, and impaired heart function were also tran-
sient and returned to normal without specific treatment.
Further investigations revealed minimal abnormalities
in the electroencephalography (EEC) without seizures,
which can be interpreted as the result of a generalized
vasculopathy with symptoms not only in the kidney, but
also in the central nervous system (CNS). Magnetic reso-
nance imaging (MRI) examination of the brain revealed
three small white matter lesions (centra semiovalia) but
no intracerebral bleeding.
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Regular FFP infusions so far maintained both platelet
levels and kidney function within normal range and pre-
vented new episodes of TTP/HUS. Up to now it remains
open whether substitution of vWF-CP will also improve
the CNS findings.
Molecular genetic analysis
After diagnosis of severe vWF-CP deficiency in the ab-
sence of ADAMTS13 autoantibodies, molecular genetic
analysis was carried out by polymerase chain reaction
(PCR) and subsequent direct sequencing of all 29 exons
of the ADAMTS13 gene as previously described [16].
Two previously undescribed candidate mutations were
detected by this approach. The first one was 1170G>C
in exon 10, predicting the exchange of tryptophane for
cysteine [W390C] and the second one was 3735G>A in
exon 27, resulting in the nonsense mutation W1245X.
W390C was identified in the patient’s father and W1245X
in the patient’s mother, respectively (Fig. 1). Whereas the
nonsense mutation can be considered causative, W390C
can only be regarded as candidate mutation since the
causative nature has not been proven by expression
studies, yet. Interpretation as common polymorphisms,
however, is rather unlikely since screening of 100 normal
alleles did not detect the here described new mutations
[16].
DISCUSSION
TTP/HUS was only recently understood as a single
syndrome. The cascade of events of several different
pathomechanisms merge to the formation of potentially
occlusive platelet aggregations associated with thrombo-
cytopenia and hemolytic anemia [3, 5]. Different organ
systems are affected: ischemia of the brain or the gas-
trointestinal tract is common and renal dysfunction may
occur [5].
Responsible is decreased vWF-CP activity (acquired,
IgG autoantibodies; congenital, ADAMTS13 gene muta-
tions) or deficiency of factors regulating the activation
of the alternative pathway of the complement system
(e.g., complement factor H (CFH) and membrane cofac-
tor protein (MCP) [5, 17–19]. It seems likely that in the
future even more factors will be identified and it has to
be assumed that TTP/HUS complex was, and probably
currently still is, underdiagnosed [16].
In support of this, Schneppenheim et al [16] recently
identified eight different ADAMTS13 gene mutations
suggesting the hereditary form of TTP in two patients
who were misdiagnosed before with idiopathic throm-
bocytopenic purpura (ITP) or Evans syndrome, and in
five out of eight patients with TTP, respectively. vWF-CP
plasma levels are not discriminating between specific di-
agnoses: in patients with HUS they vary from normal to
decreased values [3, 20, 21]. However, severe vWF-CP de-
ficiency (<5% of normal) seems to be indicative for TTP
rather than HUS [16]. Furthermore, vWF-CP levels in
patients carrying compound heterozygous ADAMTS13
gene mutations were usually not found to be higher than
5% [16].
Treatment of TTP/HUS depends on the exact diag-
nosis. If the syndrome is caused by a defect in the
vWF-CP system, both, deficiency of vWF-CP caused by
ADAMTS13 gene mutations [16], or decreased activity
of vWF-CP caused by vWF-CP autoantibodies are pos-
sible [22]. Patients with vWF-CP autoantibodies need
more aggressive therapy, including plasma exchange and
immunosuppression, while patients with the congenital
form can solely be treated by replacement of vWF-CP by
means of FFP [23–25].
In our patient, severe vWF-CP deficiency with vWF
plasma level of <3% was caused by compound het-
erozygosity for two novel ADAMTS13 gene mutations
(1170 G>C [W390C] and 3735 G>A [W1245X]. Peri-
odic (every 2 weeks) infusion of about 10 mL FFP per
kilogram body weight raised vWF-CP activity from 5%
(prior to infusion) to 10% 2 hours after infusion. vWF-
CP activity, however, decreased to 4% 8 hours after in-
fusion. Whereas the only small increase of vWF-CP is
expected and in accordance with the infused FFP volume
(10 mL/kg), the fast decline in vWF-CP activity occurs un-
expectedly. Binding of vWF-CP to endothelial surfaces,
thereby reducing vWF-CP plasma levels without reduc-
ing available intact vWF-CP, might explain this observa-
tion. To prevent clinical manifestation of new TTP/HUS
episodes, vWF-CP activity of >3% seems to be suffi-
cient. The 2-week treatment cycle in our patient is in
accordance with the literature [26, 27] and fits with the
half-life of vWF-CP of 2 to 3 days [28]. Recently, our pa-
tient developed another TTP/HUS crisis when the treat-
ment interval was mistakenly increased to more than 2
weeks. Severe thrombopenia (platelets 14,000/lL with
petechial hemorrhages) and increase of LDH (maximum
2900 U/L) were accompanied by impaired kidney func-
tion (maximum serum creatinine 460 lmol/L). Infusion of
about 25 mL FFP per kilogram body weight as single ther-
apy immediately stopped further decrease of platelets
and normalized kidney function within 4 to 5 days (serum
creatinine 71 lmol/L).
CONCLUSION
We conclude that in patients with unclear episodes
of hemolytic or thrombocytopenic episodes or HUS-like
symptoms, screening for severe vWF-CP deficiency or for
other factors causing atypical TTP/HUS should be per-
formed. Patients identified with a defect in vWF-CP can
be treated, possibly with restitutio ad integrum, by regu-
lar FFP infusions. Furthermore, patients who presented
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with hemolytic or thrombocytopenic episodes or HUS-
like symptoms in the past should be re-evaluated, at least
if diagnosis was not clear, or if restitutio ad integrum was
not achieved.
For the future, it has to be expected that the identifi-
cation of even more factors causing hemolytic or throm-
bocytopenic episodes or HUS-like symptoms will lead to
a complete new understanding and nomenclature of this
family of diseases [25].
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